scholarly journals Daunorubicin and Cytarabine Liposome (Vyxeos)

2021 ◽  
Vol 1 (10) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cost Effectiveness ◽  
Myeloid Leukemia ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Newly Diagnosed ◽  
Clinician Perspectives ◽  
Acute Myeloid

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses dunorubicin and cytarabine liposome for injection, 44 mg daunorubicin and 100 mg cytarabine per vial, IV infusion Indication: Treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes

Venetoclax (Venclexta)

2021 ◽  
Vol 1 (10) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Cost Effectiveness ◽  
Induction Chemotherapy ◽  
Low Dose ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Newly Diagnosed ◽  
Clinician Perspectives ◽  
Low Dose Cytarabine

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses venetoclax (Venclexta), 10 mg, 50 mg, and 100 mg oral tablets. Indication: In combination with azacitidine or low-dose cytarabine for the treatment of patients with newly diagnosed AML who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States

2018 ◽  
Vol 37 (2) ◽  
pp. 239-253 ◽  
Author(s):  
Eytan Stein ◽  
Jipan Xie ◽  
Emilie Duchesneau ◽  
Subrata Bhattacharyya ◽  
Umakanth Vudumula ◽  
...  
Keyword(s):  
United States ◽  
Acute Myeloid Leukemia ◽  
Cost Effectiveness ◽  
Myeloid Leukemia ◽  
The United States ◽  
Newly Diagnosed ◽  
Acute Myeloid

scholarly journals Azacitidine (Onureg)

2022 ◽  
Vol 2 (1) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Complete Remission ◽  
Myeloid Leukemia ◽  
Blood Count ◽  
Drug Class ◽  
Clinical Effectiveness ◽  
Hematopoietic Stem ◽  
Consolidation Treatment ◽  
Clinician Perspectives ◽  
Acute Myeloid ◽  
Count Recovery

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses azacitidine (Onureg), tablet 300 mg, oral. Indication: Maintenance therapy in adult patients with acute myeloid leukemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation.

scholarly journals Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Linu A. Jacob ◽  
S. Aparna ◽  
K. C. Lakshmaiah ◽  
D. Lokanatha ◽  
Govind Babu ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cost Effectiveness ◽  
Older Patients ◽  
Myeloid Leukemia ◽  
Low Dose ◽  
Study Groups ◽  
Newly Diagnosed ◽  
Treatment Groups ◽  
Low Dose Cytarabine ◽  
Acute Myeloid

Introduction. The incidence of Acute Myeloid Leukemia (AML) increases progressively with age and its treatment is challenging. This prospective case control study was undertaken to compare the safety, efficacy, and cost-effectiveness of decitabine with those of cytarabine in older patients with newly diagnosed AML who are not fit for intensive chemotherapy.Materials and Methods. 30 eligible patients above 60 years old with newly diagnosed AML were assigned to receive decitabine or cytarabine. The primary end point was overall survival (OS). The secondary objective was to compare adverse events and cost-effectiveness of therapy in the two study groups.Results. In this study, 15 patients received decitabine and 15 patients received cytarabine. The median OS was 5.5 months for each of the treatment groups. The hazard ratio between the treatment groups was 0.811 with 95% CI of 0.390 to 1.687. Toxicity profile was similar in both groups. Cost per cycle of chemotherapy in INR was 24,200 for decitabine and 1,600 for low-dose cytarabine group. Median of simplified cost-effectiveness ratio was 0.00022 for decitabine group and 0.0034 for low-dose cytarabine group.Conclusions. For elderly patients with AML, decitabine and low-dose cytarabine should be chosen based on the patient’s choice and affordability. Our study has shown that both of these agents have similar OS and toxicity. Low-dose cytarabine scores over decitabine in developing countries as it is more cost-effective.

Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France

2020 ◽  
Vol 21 (4) ◽  
pp. 543-555 ◽  
Author(s):  
Gabriel Tremblay ◽  
Clemence Cariou ◽  
Christian Recher ◽  
Mike Dolph ◽  
Patricia Brandt ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Cost Effectiveness ◽  
Myeloid Leukemia ◽  
Newly Diagnosed ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document